Cambium Bio has secured firm commitments for a conditional A$7.1 million placement, taking its proposed funding package to A$10.85 million for the pivotal Elate Ocular Phase 3 program. Completion depends on three inter-conditional shareholder resolutions at the company’s expected November AGM.
- A$7.1 million placement at A$0.48 per share
- Total proposed funding package of A$10.85 million
- Shares on issue would rise from 29.4 million to 44.2 million
- Wu investors’ combined voting power would reach approximately 31.85%
- Placement must clear shareholder approval by 30 November 2026
A$10.85 million package targets Phase 3 launch
Cambium Bio Limited (ASX:CMB) has assembled a proposed A$10.85 million funding package for the pivotal Phase 3 program for Elate Ocular, its lead treatment candidate for moderate to severe dry eye disease. The package combines a conditional A$7.1 million share placement with an undrawn A$3.75 million facility intended to pre-finance the company’s FY2027 Research and Development Tax Incentive refund.
The placement would issue 14,791,667 new shares at A$0.48 each, a 4.3% premium to Cambium’s A$0.46 closing price on 15 September. The company said the proceeds would support the Phase 3 trial, manufacturing, regulatory activities and general working capital. It did not provide a split between those uses.
Shareholder approvals carry the transaction
Nothing is settled yet. All four placement tranches are conditional on shareholder approval at the expected mid-to-late November annual general meeting, with the offers lapsing if approval is not obtained by 30 November 2026. The three required resolutions are inter-conditional, meaning failure of any one would prevent the placement from proceeding for every participant.
The most consequential approval concerns existing shareholder Chun Yi Wu and new investor Yi Chi Wu, who have confirmed they are associates. Their combined voting power would rise from approximately 18.51% to 31.85% through the issue of 8,635,056 shares, requiring approval under item 7 of section 611 of the Corporations Act and an independent expert’s report. Neither investor will be able to vote in favour of that resolution.
ZYBT, Cambium’s largest shareholder and a related party because it holds more than 30% and is chaired by Cambium non-executive director Dr Sebastian Tseng, is subscribing for 4,677,444 shares worth approximately A$2.25 million. Its voting power would fall from about 36.78% to 35.06%, so the issue requires approval under ASX Listing Rule 10.11 but not under section 611 item 7. The board, with Dr Tseng abstaining, has determined that the terms are arm’s length.
Dilution and trial execution remain the next tests
If approved, shares on issue would increase from 29.43 million to 44.22 million, before considering any later capital activity. The placement price is above the recent market price, but the additional shares would materially expand the equity base while concentrating a larger voting position among the Wu investors and leaving ZYBT with more than one-third of the company.
The RDTI facility itself was undrawn as at the announcement date and is secured only against the FY2027 refund receivable and its proceeds. The immediate question is therefore not simply whether Cambium has announced enough funding on paper, but whether the approvals, financing drawdown and clinical execution align quickly enough to move Elate Ocular into its pivotal Phase 3 program.
Bottom Line?
The funding target is substantial for Cambium, but the package remains conditional: shareholder votes, the undrawn RDTI facility and Phase 3 execution are the key gates ahead.
Questions in the middle?
- Will shareholders approve all three inter-conditional resolutions at the November AGM?
- When will Cambium draw the A$3.75 million RDTI pre-financing facility?
- Can the proposed funding package carry Elate Ocular through the pivotal Phase 3 trial and associated manufacturing and regulatory work?